R&D
Service
Our assays reveal the low-level of brain somatic mutations as genetic causes in up to 40% of childhood intractable epilepsy and match patients to approved targeted therapies, and clinical trials — giving doctors and patients powerful actionable insights for navigating drug-resistant epilepsy.
 We provide genomic test of low-level somatic mutations in epileptic disorders.
Revealing the low-level of brain somatic mutations as genetic causes in up to 40% of childhood intractable epilepsy
Matching patients to approved targeted therapies and clinical trials
Giving doctors and patients powerful actionable insights for navigating drug-resistant epilepsy
Service Inquiry
Please contact us if you are interested in our service.
Phone : +82–70–5222-2770
Email : sovargen@sovargen.com